Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices

Fibrogenesis & Tissue Repair

Raghavendra Pralhada Rao¹  Anup M Oommen¹  Somesh Baggavalli¹  Madhusudhan B Reddy¹  Vibha Haridas¹  Nimisha R Kumar¹  Balamuralikrishna Vasamsetti¹  Khaiser Mehdi Khan¹  Nethra Siddaraju¹  Satish Kumar Sadasivan¹ 

[1] Connexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore 560078, India

关键词: Stellate cells;    Myofibroblast;    Screening platform;    Fibrosis;    Liver slice;   

Others  :  1121598
DOI  :  10.1186/s13069-014-0017-2

 received in 2014-09-25, accepted in 2014-12-05,  发布年份 2014

【 摘 要 】

Background

Precision-cut liver slices present different cell types of liver in a physiological context, and they have been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using toxicants like carbon tetrachloride is of less relevance to human disease conditions. Our aim for this study was to establish physiologically relevant conditions in vitro to induce fibrotic phenotypes in the liver slices.

Results

Precision-cut liver slices of 150 μm thickness were obtained from female C57BL/6 J mice. The slices were cultured for 24 hours in media containing a cocktail of 10 nM each of TGF-β, PDGF, 5 μM each of lysophosphatidic acid and sphingosine 1 phosphate and 0.2 μg/ml of lipopolysaccharide along with 500 μM of palmitate and were analyzed for triglyceride accumulation, stress and inflammation, myofibroblast activation and extracellular matrix (ECM) accumulation. Incubation with the cocktail resulted in increased triglyceride accumulation, a hallmark of steatosis. The levels of Acta2, a hallmark of myofibroblast activation and the levels of inflammatory genes (IL-6, TNF-α and C-reactive protein) were significantly elevated. In addition, this treatment resulted in increased levels of ECM markers - collagen, lumican and fibronectin.

Conclusions

This study reports the experimental conditions required to induce fibrosis associated with steatohepatitis using physiologically relevant inducers. The system presented here captures various aspects of the fibrosis process like steatosis, inflammation, stellate cell activation and ECM accumulation and serves as a platform to study the liver fibrosis in vitro and to screen small molecules for their antifibrotic activity.

【 授权许可】

   
2015 Sadasivan et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Friedman SL: Liver fibrosis – from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-53.
• [2]Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115:209-18.
• [3]Kmiec Z: Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001, 161:III-XIII. 1–151
• [4]Marra F: Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999, 31:1120-30.
• [5]Van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P: Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro 2007, 21:545-57.
• [6]Chen CZ, Raghunath M: Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair 2009, 2:7. BioMed Central Full Text
• [7]Chen CZ, Peng YX, Wang ZB, Fish PV, Kaar JL, Koepsel RR, et al.: The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol 2009, 158:1196-209.
• [8]van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P: Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. J Hepatol 2006, 45:696-703.
• [9]van de Bovenkamp M, Groothuis GM, Draaisma AL, Merema MT, Bezuijen JI, van Gils MJ, et al.: Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci 2005, 85:632-8.
• [10]Westra IM, Oosterhuis D, Groothuis GM, Olinga P: The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One 2014, 9:e95462.
• [11]Constandinou C, Henderson N, Iredale JP: Modeling liver fibrosis in rodents. Methods Mol Med 2005, 117:237-50.
• [12]Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis? Hepatology 1983, 3:112-20.
• [13]Westra IM, Oosterhuis D, Groothuis GM, Olinga P: Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol Appl Pharmacol 2014, 274:328-38.
• [14]Gressner AM, Weiskirchen R, Breitkopf K, Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002, 7:d793-807.
• [15]Liu Y, Wen XM, Lui EL, Friedman SL, Cui W, Ho NP, et al.: Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest 2009, 89:1152-60.
• [16]Liu X, Hu H, Yin JQ: Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006, 26:8-22.
• [17]Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-73.
• [18]Pralhada Rao R, Vaidyanathan N, Rengasamy M, Mammen Oommen A, Somaiya N, Jagannath MR: Sphingolipid metabolic pathway: an overview of major roles played in human diseases. J Lipids 2013, 2013:178910.
• [19]Shea BS, Tager AM: Sphingolipid regulation of tissue fibrosis. Open Rheumatol J 2012, 6:123-9.
• [20]Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM: Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010, 43:662-73.
• [21]Li C, Jiang X, Yang L, Liu X, Yue S, Li L: Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 2009, 175:1464-72.
• [22]Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, et al.: S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 2010, 85:484-93.
• [23]Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A: Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 2002, 43:2049-55.
• [24]Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S: Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol 1994, 267:C204-10.
• [25]Birgbauer E, Chun J: New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 2006, 63:2695-701.
• [26]Yin Z, Watsky MA: Chloride channel activity in human lung fibroblasts and myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1110-6.
• [27]Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, et al.: Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008, 58:2553-64.
• [28]Yang L, Seki E: Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol 2012, 3:138.
• [29]Cong M, Iwaisako K, Jiang C, Kisseleva T: Cell signals influencing hepatic fibrosis. Int J Hepatol 2012, 2012:158547.
• [30]Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S: Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol 2014, 20:9038-49.
• [31]Day CP, James OF: Steatohepatitis: a tale of two “hits”? Gastroenterology 1998, 114:842-5.
• [32]Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, et al.: Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 2009, 19:996-1005.
• [33]Berlanga A, Guiu-Jurado E, Porras JA, Auguet T: Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014, 7:221-39.
• [34]Yeniova AO, Kucukazman M, Ata N, Dal K, Kefeli A, Basyigit S, et al.: High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease. Hepatogastroenterology 2014, 61:422-5.
• [35]Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R: Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis 2011, 20:153-9.
• [36]Manco M, Marcellini M, Giannone G, Nobili V: Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 127:954-60.
• [37]Choi I, Kang HS, Yang Y, Pyun KH: IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clin Exp Immunol 1994, 95:530-5.
• [38]Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y: Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leukoc Biol 1994, 55:120-6.
• [39]Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, et al.: Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010, 5:e11049.
• [40]Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, Cederbaum AI: Ethanol and arachidonic acid increase alpha 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. Role of H2O2 and cyclooxygenase-2. J Biol Chem 2000, 275:20136-45.
• [41]Safadi R, Friedman SL: Hepatic fibrosis–role of hepatic stellate cell activation. MedGenMed 2002, 4:27.
• [42]Poli G, Parola M: Oxidative damage and fibrogenesis. Free Radic Biol Med 1997, 22:287-305.
• [43]Rockey DC, Weymouth N, Shi Z: Smooth muscle alpha actin (Acta2) and myofibroblast function during hepatic wound healing. PLoS One 2013, 8:e77166.
• [44]Rockey DC, Boyles JK, Gabbiani G, Friedman SL: Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992, 24:193-203.
• [45]Cassiman D, Roskams T, van Pelt J, Libbrecht L, Aertsen P, Crabbe T, et al.: Alpha B-crystallin expression in human and rat hepatic stellate cells. J Hepatol 2001, 35:200-7.
• [46]Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-72.
• [47]Clouthier DE, Comerford SA, Hammer RE: Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 1997, 100:2697-713.
• [48]Ghosh AK, Vaughan DE: PAI-1 in tissue fibrosis. J Cell Physiol 2012, 227:493-507.
• [49]Nie QH, Zhang YF, Xie YM, Luo XD, Shao B, Li J, et al.: Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models. World J Gastroenterol 2006, 12:3044-9.
• [50]Masuda H, Fukumoto M, Hirayoshi K, Nagata K: Coexpression of the collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1994, 94:2481-8.
• [51]Kanuri G, Bergheim I: In vitro and in vivo models of Non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 2013, 14:11963-80.
• [52]de Graaf IA, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, et al.: Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 2006, 34:591-9.